REGiMMUNE Corporation (RGI) Appointed Joseph “Joe” McCracken as a board
Tokyo, Japan., Dec 25, 2015 – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives, and serves on the Board of Alkahest, Inc., Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.
“Joe is a great addition to our management team. His depth of experience in working with global mega pharmas and emerging biotechnology companies, as well as his proven abilities to manage business development will be invaluable to RGI.” stated Yasuyuki Ishii , president and chief executive officer of RGI.
“I am thrilled to join RGI at this point in the company’s journey,” stated Dr. McCracken. “RGI has a strong leadership team that is committed to develop novel products for patients with serious medical conditions. Significant progress has been made over the past years in developing its leading program, RGI-2001, as well as in building a pipeline of innovative products. I look forward to participating in continued value creation for patients and contributing to REGiMMUNE’s corporate development.”